Skip to content

Intravitreal Injection Site and Perceived Pain

The Effect of Entry Site Distance From Limbus on Perceived Pain During Intravitreal Injection of Anti-VEGF (Vascular Endothelial Growth Factor) Agents

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05640895
Enrollment
53
Registered
2022-12-07
Start date
2022-11-14
Completion date
2024-09-09
Last updated
2025-01-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain

Keywords

Intravitreal injection, Retinal diseases, Age-related macular degeneration, Diabetic retinopathy, Retinal vein occlusion, Limbus, Quadrants (regions) of the eye, Injection site, Pseudophakic/aphakic eyes, Phakic eyes, Pars plana, Ciliary body, Vitrectomy, Crystalline lens, Retina, Bevacizumab, Ranibizumab, Aflibercept, Diabetic macular edema, Anti-VEGF (Vascular Endothelial Growth Factor), Vabysmo

Brief summary

The objective of this study is to explore the perception of pain during intravitreal injection related to the distance of the entry site from the limbus.

Detailed description

In this pilot cross-over study, the investigators aim at exploring a factor not studied yet on the perception of pain during the injection procedure, and that is the distance of the entry site from the limbus. Study population: Pseudophakic patients needing multiple intravitreal injections. In case of bilateral eligibility, one eye per patient will be included (randomly- based on a random chart). Intervention: two injections per eye, will be included in the study. All steps of the technique will be similar between the two injections except for the entry site distance from the limbus, which will be 3.5 in one and 4.00 mm in the other. To prevent bias, the first injection entry distance will be randomly selected (based on a randomized chart). The patient is blind to the entry distance, and a questionnaire with a visual analog pain scale will be given to the patient by a technician (to prevent any bias) to be filled after the injection. The analog pain scale is a scale of numbers from 0 to 10 representing the degree of patient's perceived pain. A score of 0 indicates no perception of pain; a score of 10 indicates a perception of the worst pain possible. The scale is also illustrated with face emojis corresponding to a written description of pain perception from no perception of pain, represented by a green, fully smiling face to perception of the worst pain possible, represented by a red, crying, fully frowning face.

Interventions

PROCEDUREIntravitreal injection site

Intravitreal injections will be made at varying sites; patients will report on pain perception

Sponsors

The University of Texas Medical Branch, Galveston
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
Yes

Inclusion criteria

* Age 18 -100 years * Diagnosis of diabetic macular edema, age related macular degeneration, or retinal vein occlusion * Treated with bevacizumab, ranibizumab, aflibercept * The need for at least two intravitreal injections * Pseudophakia

Exclusion criteria

* Texas Department of Corrections medical records * Under 18 years-of-age * First intravitreal injection experience of patient

Design outcomes

Primary

MeasureTime frameDescription
Visual scale analogues for painImmediately post-injectionSelf-reported perception of pain according to analogue pain scale. The analog pain scale is a scale of numbers from 0 to 10 representing the degree of patient's perceived pain. A score of 0 indicates no perception of pain; a score of 10 indicates a perception of the worst pain possible. The scale is also illustrated with face emojis corresponding to a written description of pain perception from no perception of pain, represented by a green, fully smiling face to perception of the worst pain possible, represented by a red, crying, fully frowning face.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026